News

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid ...
Taiwan News2h
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC) Median Overall Survival of 17.3 months in ...
Le Lézard1h
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
Revvity, Inc. , today announced the launch of three Mimixtm reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting ...
Le Lézard1h
HepQuant Achieves ISO 13485 Certification to Support Scaling of HepQuant DuOtm to Global Clinical Trials
HepQuant, LLC, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, is proud to announce ISO 13485 certification as its latest milestone in operational ...
The Manila Times2h
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
BioCryst will present four abstracts at the meeting: Impact of Berotralstat on Quality of Life among Patients with Hereditary ...
BioPharma Dive21h
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising
An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...
PipelineReview.com6h
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
BASEL, Switzerland I June 1, 2025 I Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety ...